Fundraising Fox

Fusion Pharmaceuticals

Founded 2014 · 60 employees on LinkedIn · 9 known investors

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells. A spin-out of the Centre for Probe Development and Commercialization, it focuses on radiopharmaceuticals for cancer treatment.

BiotechHealthtech

Investors · 9

FACIT (Fight Against Cancer Innovation Trust)Toronto · $1.1M
HealthCapStockholm
Lumira VenturesToronto · $1M – $10M
Seroba Life SciencesDublin · $540K – $7.6M
Venture OntarioToronto
Ysios CapitalBarcelona · $5.4M – $21.6M
Adams Street PartnersreportedChicago · $150M – $750M
Genesys CapitalreportedToronto · $730K – $3.6M
Johnson & Johnson Innovation – JJDCreportedNew Brunswick

Competitors · 1

by search overlap
Radiuspharm17 shared keywordsRadius is a biopharmaceutical company focused on bone health and related therapeutic areas for underserved patient populations. It markets commercial products in the U.S., including TYMLOS (abaloparatide) injection and BINOSTO (alendronate sodium).

Companies competing with Fusion Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Fusion Pharma fetches $213m in IPO - Global Venturingglobalventuring.com · Jun 2020Hamilton's Fusion Pharmaceuticals Raises $26 Million CAD - Innovation Factoryinnovationfactory.ca · Jan 2020Precision oncology startup Fusion Pharmaceuticals raises $26 million CAD | BetaKitbetakit.com · Jan 2020Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing - HealthCaphealthcap.eu · Apr 2019Fusion Pharmaceuticals Secures Additional $21M; Closes $46M Series A financing - FinSMEsfinsmes.com · Sep 2017Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments - Fusion Pharmafusionpharma.com · Feb 2017

Frequently asked questions

What does Fusion Pharmaceuticals do?
Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells. A spin-out of the Centre for Probe Development and Commercialization, it focuses on radiopharmaceuticals for cancer treatment.
Who are Fusion Pharmaceuticals's investors?
Fusion Pharmaceuticals's investors include FACIT (Fight Against Cancer Innovation Trust), HealthCap, Lumira Ventures, Seroba Life Sciences, Venture Ontario, Ysios Capital, Adams Street Partners, Genesys Capital and 1 more.